
of Illinois for coordinated management during discovery, the early bellwether trials and any preliminary attempts to negotiate settlement offers. Similar centralized management for the cases has been put in place for state court cases filed in New Jersey and Pennsylvania.
Plaintiffs’ attorneys recently asked Judge Herndon to consolidate
several cases for the second and third trials, arguing that trying cases one
plaintiff at a time would “commit this litigation to a lifespan of eternity.”
Plaintiffs indicated that there has been no movement by Bayer towards a Yaz settlement agreement, and suggested that efficiencies would be
served by trying several cases at a time after the first bellwether trial. Judge
Herndon has stated that the court plans to move towards “meaningful” settlement
negotiations once the initial trials have been held, which are designed to help
gauge how juries are likely to respond to evidence.
Yaz and Yasmin are birth control pills that contain a newer type of
progestin, known as drospirenone, which has been linked to an increased risk of
blood clots and other injuries. The Yaz and Yasmin litigation also involves cases filed over a newer
version of the birth control pills, sold as Beyaz, as well as generic
equivalents, such as Ocella and Gianvi. Although
the first trials are approaching, the number of lawsuits is expected to
continue to grow as Yaz and Yasmin
lawyers review and file additional cases in the coming months
and years for women who have experienced health problems from the birth control
pills.
No comments:
Post a Comment